ArticleRheumatology advances in practice2025
Insight from convergent validity of assessment of systemic sclerosis-associated Raynaud phenomenon with nailfold capillaroscopy.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The assessment of systemic sclerosis-associated Raynaud phenomenon (ASRAP) questionnaire was recently developed. We tested the convergent validity of the ASRAP instrument with patient demographics and capillary morphology on nailfold capillaroscopy (NFC). Methods: Participants completed the ASRAP (range 20-80; higher scores unfavourable) and underwent NFC using Dinolite™. We collected demographic and relevant clinical data. Two blinded assessors classified NFC images as 'scleroderma pattern' present or absent and recorded specific abnormalities. We assigned the NFC semi-quantitative score (range 0-3) based on the frequency of these abnormalities. Descriptive statistics were generated, and regression and correlation analyses were used to evaluate associations between ASRAP, NFC and clinical factors. Results: Seventy-five patients [87% women, 78% white, 77% with limited cutaneous SSc] with a mean (SD) age of 58 (14) were recruited from scleroderma clinics. ASRAP scores were 11.2 points higher in women compared with men with other significant variables held constant. The NFC semi-quantitative score weakly correlated with ASRAP (Spearman's σ = 0.23, Conclusion: In SSc patients, females reported higher ASRAP scores. Greater proportion of 'scleroderma pattern' NFC abnormalities as well as specific abnormalities like dilated capillaries and capillary dropout were associated with higher ASRAP providing mechanistic insight and supporting the construct validity of ASRAP for assessing SSc-RP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.